(Q34069810)

30 July 2017

1 reference

title

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time (English)

1 reference

30 July 2017

1 reference

Dudley MN

1

1 reference

30 July 2017

Ambrose PG

series ordinal

2

1 reference

30 July 2017

publication date

1 October 2000

1 reference

Current Opinion in Microbiology

30 July 2017

published in

1 reference

30 July 2017

volume

3

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

515-521

1 reference

ARTs versns ASTs: where are we going?

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Limitations of single point pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Role for Dual Individualization with Cefmenoxime

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

Clinical pharmacokinetics of ceftriaxone

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2800%2900132-6

7 January 2021

10.1016/S1369-5274(00)00132-6

Identifiers

DOI

1 reference

release_pwfeopnkbndelkmml7okh3w27u

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pwfeopnkbndelkmml7okh3w27u

24 November 2022

mapped directly with Wikidata item

1 reference